WAM
GALT icon

Wolverine Asset Management’s Galectin Therapeutics GALT Stock Holding History

Wolverine Asset Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-6,715
Closed -$15K – 1326
2017
Q1 		$15K Hold
6,715
– – ﹤0.01% 1107
2016
Q4 		$6K Hold
6,715
– – ﹤0.01% 1137
2016
Q3 		$7K Hold
6,715
– – ﹤0.01% 1176
2016
Q2 		$9K Hold
6,715
– – ﹤0.01% 1147
2016
Q1 		$9K Hold
6,715
– – ﹤0.01% 1073
2015
Q4 		$11K Hold
6,715
– – ﹤0.01% 1394
2015
Q3 		$15K Hold
6,715
– – ﹤0.01% 1512
2015
Q2 		$18K Buy
+6,715
New +$20.2K ﹤0.01% 1501
2014
Q1 		– Sell
-55,439
Closed -$447K – 2566
2013
Q4 		$447K Buy
+55,439
New +$512K 0.01% 818

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Wolverine Asset Management's GALT Position: Q2 2017 in Review

Wolverine Asset Management sold out of Galectin Therapeutics (GALT) in Q2 2017, closing a stake of 6,715 shares — an estimated $15K sold.

Wolverine Asset Management first reported a position in GALT in Q4 2013 and held it in 9 quarters. The position peaked at $447K in Q4 2013. 52 funds tracked by Wall St. Rank hold GALT as of Q2 2017.

  • Wolverine Asset Management reported no remaining Galectin Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Wolverine Asset Management sold 6,715 Galectin Therapeutics shares in Q2 2017, an estimated $15K.
  • Wolverine Asset Management first reported a position in Galectin Therapeutics in Q4 2013 and held it in 9 quarters.
  • Wolverine Asset Management's Galectin Therapeutics position peaked at $447K in Q4 2013.
  • 52 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2017.

Based on Wolverine Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.